ORGO Q2 2023 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$117M-3.4% YoY

Gross Profit

$91M77.6% margin

Operating Income

$10M8.3% margin

Net Income

$5M4.5% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$1M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$450M

Total Liabilities

$179M

Stockholders' Equity

$271M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$121M	-3.4%
Gross Profit	$91M	$95M	-4.0%
Operating Income	$10M	$12M	-18.3%
Net Income	$5M	$9M	-39.2%

Revenue Segments

Advanced Wound care

$110M94%

Surgical and Sports Medicine

$7M6%